Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib.

Afatinib, an irreversible blocker of the ErbB family of proteins (epidermal growth factor receptor [EGFR], human epidermal growth factor [HER]-2, HER-3 and HER-4), is used to treat advanced EGFR mutation-positive, non-small-cell lung cancer. Because afatinib irreversibly blocks these receptors, its effects last longer and are stronger than those of conventional EGFR inhibitors (EGFRIs) [1]. Similar to other EGFRIs, afatinib can produce adverse effects that affect the skin, including papulopustular [...]